Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E McCartney

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 1995
Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptideA J George, F Jamar, M S Tai, et al.
Protein Engineering|March 1, 1995
Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptidesJ E McCartney, M S Tai, R M Hudziak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1995
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugationG P Adams, J E McCartney, E J Wolf, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administrationG P Adams, J E McCartney, E J Wolf, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|September 1, 1996
Single-chain Fv radioimmunotargetingJ S Huston, A J George, G P Adams, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 1995
Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptideA J George, F Jamar, M S Tai, et al.
Protein Engineering|March 1, 1995
Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptidesJ E McCartney, M S Tai, R M Hudziak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1995
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugationG P Adams, J E McCartney, E J Wolf, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administrationG P Adams, J E McCartney, E J Wolf, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|September 1, 1996
Single-chain Fv radioimmunotargetingJ S Huston, A J George, G P Adams, et al.
Pageof 3